IMMB.US Immunotech Laboratories Inc
- Market cap
- USD 110.00
- P/E
- -
- P/B
- 0.01x
- ROE
- -14.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2009.
Is IMMB.US undervalued?
Graham numberThe Graham number of Immunotech Laboratories Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Immunotech Laboratories Inc fundamental analysis
No fundamental analysis for Immunotech Laboratories Inc yet.
Immunotech Laboratories Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Immunotech Laboratories Inc
Immunotech Laboratories, Inc. develops and commercializes proprietary proteins for use in treating human immunodeficiency virus (HIV), acquired immune deficiency syndrome (AIDS), hepatitis, and other immuno-related disorders. Its flagship compound is ITV-1 (immune therapeutic vaccine), a suspension of irreversible pepsin fraction that is used in the treatment of HIV/AIDS and Hepatitis C, as well as to modulate the immune system. The company is headquartered in Monrovia, Cali…
Full company profileImmunotech Laboratories Inc financial statements
Immunotech Laboratories Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2009 |
|---|---|
| Income Statement | |
| Revenue | 0.00 |
| Gross Profit | 0.00 |
| Operating Income | -959K |
| Net Income | -978K |
| Balance Sheet | |
| Total Assets | 10.5M |
| Total Liabilities | 3.70M |
| Shareholders' Equity | 6.75M |
| Cash & Short-term Investments | 4.80K |
| Cash Flow | |
| Capital Expenditure | 0.00 |
| Ratios | |
| ROE | -14.5% |
| ROA | -9.4% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
Immunotech Laboratories Inc dividends
Immunotech Laboratories Inc has not paid dividends in the last 1 fiscal years.
Last stock split: 1:100 on Feb 26, 2009.
Who owns Immunotech Laboratories Inc
Ownership data of Immunotech Laboratories Inc is not available yet.
Immunotech Laboratories Inc company profile
- Company name
- Immunotech Laboratories Inc
- Ticker
- IMMB.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 4
- Fiscal year end
- December
- Address
- 120 West Pomona Avenue, Monrovia, CA, United States, 91016
- Phone
- 626-538-4779
- Website
- immunotechlab.com
About Immunotech Laboratories Inc
Immunotech Laboratories, Inc. develops and commercializes proprietary proteins for use in treating human immunodeficiency virus (HIV), acquired immune deficiency syndrome (AIDS), hepatitis, and other immuno-related disorders. Its flagship compound is ITV-1 (immune therapeutic vaccine), a suspension of irreversible pepsin fraction that is used in the treatment of HIV/AIDS and Hepatitis C, as well as to modulate the immune system. The company is headquartered in Monrovia, California. As of June 14, 2017, Immunotech Laboratories, Inc. operates as a subsidiary of Enzolytics, Inc.
Immunotech Laboratories Inc management
3- Mr. Harry H. Zhabilov Jr., BSc, McS ScienceFounder, Vice Chairman, President, Chief Science Officer & Secretary · born 1967
- Billy RayCFO, Executive of Business and Development & Member of Advisory Board
- Mr. Adam S. Tracy Esq., J.D., MBALegal Counsel · born 1976